Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.
Age ≥ 18 years
Participating to the prevention campain "Mai Poumons 2026" on 09 Mai 2026
Contre-indication to perform a spirometry : hemoptysy, pneumothorax, myocardal infarction <1month, thoracic anevrism, recent ophtalmologic, abdominal or thoracic surgery
Unable to perform a spirometry (understanding, coordination)
Patient under legal protection
Patient pregnant or breasting
Population attending the "9 Mai Poumon 2026" prevention campaign
Cohort
Prospective
Spirometry
Diagnostic testSpirometry to identify airflow obstruction and PRISm (Preserved ration impaired spirometry)
Prevalence of newly diagnosed airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population
Percentage of AO and PRISm detected
Description of the clinical characteristics of patients with and without Airflow Obstruction / with and without PRISm
Percentage of presence of symptoms, specific treatment
Description of the population participating to the prevention campaing
Percentage of presence of tabagism
Evaluation of the number of patients diagnosed with airflow obstruction or Prism and who attend a consult with a medical doctor after the prevention campain
Percentage of patients with a medical follow-up at 6 months
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
